# reload+after+2024-01-21 22:46:06.294973
address1§4551 Kennedy Commerce Drive
city§Houston
state§TX
zip§77032
country§United States
phone§713 400 6400
website§https://www.markertherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.
fullTimeEmployees§67
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Juan F. Vera M.D.', 'age': 43, 'title': 'Co-Founder, CEO, President & Director', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 529123, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Elizabeth  Donnelly', 'title': 'Director of Administration', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Edmund  Cheung', 'title': 'Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Nadia  Agopyan Ph.D.', 'title': 'Senior Vice President of Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Monic  Stuart M.D.', 'title': 'Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Gerald  Garrett', 'title': 'Senior Vice President of Clinical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael J. Loiacono', 'age': 57, 'title': 'Treasurer & Secretary', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 287981, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Robert Z. Florkiewicz Sr.', 'title': 'Senior Director of Molecular Biology & Virology', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.512
priceToSalesTrailing12Months§5.03246
currency§USD
dateShortInterest§1702598400
forwardEps§-3.4
exchange§NCM
quoteType§EQUITY
shortName§Marker Therapeutics, Inc.
longName§Marker Therapeutics, Inc.
firstTradeDateEpochUtc§1026826200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f52316f7-d523-378a-bebe-a89c89d1c289
gmtOffSetMilliseconds§-18000000
targetHighPrice§12.5
targetLowPrice§12.5
targetMeanPrice§12.5
targetMedianPrice§12.5
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§1
quickRatio§6.317
grossMargins§-1.8369
ebitdaMargins§-2.57608
trailingPegRatio§None
